A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer
Vladimir Lazar(Institut Gustave Roussy), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Ludovic Lacroix(Centre National de la Recherche Scientifique), Antoine Yver(Daiichi Sankyo (United States)), Joel Haspel(Oracle (United Kingdom)), Karina Eterovic(The University of Texas MD Anderson Cancer Center), André Lopes Carvalho(Hospital de Câncer de Barretos), Trent Haywood(Blue Cross Blue Shield Association), Yudi Pawitan(Karolinska Institutet), Susan Galbraith(AstraZeneca (United Kingdom)), Eitan Rubin(Ben-Gurion University of the Negev), Steve Laderman(Agilent Technologies (United States)), Benjamin Besse(Institut Gustave Roussy), Serge Koscielny(Institut Gustave Roussy), Gerald Batist(Jewish General Hospital), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Zhengyin Kan(Pfizer (United States)), Angel Porgador(Ben-Gurion University of the Negev), Hilario Mata(The University of Texas MD Anderson Cancer Center), Komal Jhaveri(Memorial Sloan Kettering Cancer Center), C.S. Pramesh(Homi Bhabha National Institute), Khee Chee Soo(National Cancer Centre Singapore), Dingwei Ye(Fudan University Shanghai Cancer Center), Catherine Bresson(WIN Consortium), Philippe Morice(Inserm), Robert Dann(University of Pennsylvania), Guillaume Meurice(Institut Gustave Roussy), Gary A. Palmer(Foundation Medicine (United States)), Stéphane Depil(Servier (France)), Raanan Berger(Tel Aviv University), M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jeanne Kehren(Sanofi (France)), Jonathan R. Dry(AstraZeneca (United Kingdom)), Ioana Berindan‐Neagoe(Iuliu Hațieganu University of Medicine and Pharmacy), Gilles Vassal(Université Paris-Saclay), Philippe Vielh(Hôpital américain de paris), Andrew Mortlock(AstraZeneca (United Kingdom)), Amir Onn(Tel Aviv University), Iman Osman(New York University), Michel Ducreux(Université Paris-Saclay), Amal Al‐Omari(King Hussein Cancer Center), Alexandru Irimie(Institute of Oncology Prof. Dr. Ion Chiricuta), Pierre Validire, Johan Hansson(Karolinska Institutet), Thierry Le Chevalier(Université Grenoble Alpes), Jesús Gómez-Navarro(University of Alabama at Birmingham), Hovav Nechushtan(University Medical Center), Jean‐François Martini(Hôpital Necker-Enfants Malades), Marco A. Pierotti(Società Italiana di Nefrologia)
Cited by 31
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k